Roche ’s emicizumab for haemophilia A meets primary endpoint in phase III study

Roche today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with haemophilia A and inhibitors to factor VIII.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news